Other studies have investigated its variation in several pathological conditions, revealing that COVID-19 patients with common comorbidities of cancer and chronic diseases may show higher ACE2 expression levels, which could lead to an increased susceptibility to multi-organ damage [6]. Here, ACE2 is linked to COVID-19.